Clinical Trial Update: Oculusgen (Ologen) Glaucoma MMC Control in Estonia [Phase 3]

View source ↗

Summary

Phase 3 clinical trial of Oculusgen (Ologen) collagen matrix for glaucoma completed in Estonia, evaluating several glaucoma subtypes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angle-closure Glaucoma
• Juvenile Open-angle Glaucoma
• Neovascular Glaucoma
• Open-angle Glaucoma
• Uveitic Glaucoma

Drugs mentioned

• Ologen

Snippet

Sponsor: Pro Top & Mediking Company Limited | Conditions: Open Angle Glaucoma, Angle Closure Glaucoma | Phase 3 | Status: COMPLETED